Adults and children living with a rare kidney-scarring condition called focal segmental glomerulosclerosis now have the first drug ever cleared by the Food and Drug Administration specifically for their disease. The agency approved sparsentan, sold under the brand name Filspari, after a phase 3 trial showed the drug reduced protein leakage in urine more effectively than the standard blood-pressure medication irbesartan. The approval arrived despite the trial’s failure to demonstrate a statistically significant difference in the rate of kidney-function decline at week 108, raising pointed questions about what kind of evidence should be enough to green-light treatments for diseases that can silently push patients toward dialysis or transplant.
Why Filspari’s FSGS clearance changes the treatment calculus
FSGS damages the tiny filters inside the kidneys, replacing healthy tissue with scar tissue. Patients often have no symptoms until significant function is already lost. Until Filspari, clinicians managed the disease with off-label blood-pressure drugs and immunosuppressants, none of which carried an FDA-approved indication for FSGS. The agency’s decision to approve Filspari for this population gives nephrologists a labeled option and, just as critically, creates a reimbursement pathway that off-label prescriptions often lack.
The approval also rested on an accelerated regulatory framework tied to proteinuria reduction, a surrogate marker. Proteinuria, the spillage of protein into urine, correlates with kidney damage, but it is not the same as proving a drug preserves kidney function over years. That distinction matters because the DUPLEX phase 3 trial, which compared sparsentan to irbesartan in primary FSGS, did not find a statistically significant difference in estimated glomerular filtration rate (eGFR) slope at week 108, according to results published in The New England Journal of Medicine. The eGFR slope is the standard measure of how fast kidneys lose filtering capacity. Approving a drug on the strength of a surrogate while the harder endpoint missed significance sets a regulatory template that other drugmakers are watching closely.
DUPLEX trial data and the proteinuria precedent
The DUPLEX study (NCT03493685) was a randomized, double-blind, active-controlled trial in patients with primary FSGS. Participants received either sparsentan or irbesartan, and the primary analysis measured changes in proteinuria alongside the trajectory of eGFR decline. Sparsentan lowered proteinuria more than irbesartan, satisfying the prespecified surrogate endpoint and supporting the case that blocking both endothelin and angiotensin receptors can better protect the kidney’s filtering units than blocking angiotensin alone.
Yet the peer-reviewed publication in the New England Journal of Medicine confirmed that the eGFR slopes at 108 weeks did not separate in a statistically robust way. In other words, the drug clearly improved a laboratory marker of kidney stress but did not convincingly slow the measured loss of kidney function over roughly two years. The FDA weighed these mixed results and still moved forward, citing the unmet need in a rare disease with no approved alternatives and the biological plausibility that sustained proteinuria reductions could translate into long-term benefit if maintained.
Sparsentan also holds orphan-drug status for FSGS, a designation that brings development incentives and seven years of market exclusivity for the indication. That protection can shape how quickly competitors enter the space and may encourage the sponsor to invest in the confirmatory studies that regulators are increasingly demanding when approvals hinge on surrogate endpoints.
A parallel data set from a different kidney disease strengthens the case that proteinuria-based approvals are becoming a regulatory pattern. The FDA granted accelerated approval to Voyxact, a monoclonal antibody called sibeprenlimab-szsi, for primary immunoglobulin A nephropathy (IgAN). That decision similarly relied on proteinuria reduction at nine months versus placebo, with the agency explicitly noting that long-term slowing of kidney-function decline had not yet been proved. Two rare glomerulopathies, two accelerated approvals, both anchored to the same surrogate: the trend line is clear.
Separate two-year results from the PROTECT trial in IgA nephropathy, published in The Lancet, showed sparsentan produced durable proteinuria reductions and a more favorable eGFR slope than irbesartan. Those findings are encouraging for the drug’s mechanism but apply to a different disease with distinct immunologic drivers. No equivalent two-year peer-reviewed eGFR data exist yet for sparsentan in FSGS, which means the strongest published evidence for kidney-function preservation comes from an indication the drug was not originally designed to treat.
Gaps in the FSGS evidence and what patients should track
The most pressing open question is whether proteinuria reduction in FSGS will translate into fewer patients reaching kidney failure or needing dialysis and transplant. The DUPLEX trial’s week 108 eGFR result did not confirm that link. Post-marketing studies or longer follow-up from the existing cohort will need to fill the gap, and regulators are likely to scrutinize whether any emerging signal is strong enough to convert Filspari’s status from an accelerated approval into a traditional, fully confirmed one.
For patients and families, that uncertainty does not necessarily mean they should avoid the drug, but it does change how they and their clinicians frame expectations. Rather than assuming Filspari will definitively delay kidney failure, patients should understand that the clearest proven effect is a reduction in proteinuria. They can then work with their nephrologist to decide whether that benefit, along with the possibility of longer-term kidney preservation, outweighs the drug’s risks and monitoring requirements.
In practical terms, anyone starting Filspari for FSGS should pay close attention to several metrics. Regular urine tests to track protein levels will show whether the drug is achieving its intended biological effect. Serial measurements of eGFR and serum creatinine will help detect any early signs that the kidneys are either stabilizing or continuing to decline at the same pace. Blood pressure, fluid status, and electrolyte levels, particularly potassium, also warrant close monitoring, since sparsentan acts on pathways that can influence all three.
Shared decision-making becomes especially important in this context. Some patients may prioritize trying the first approved therapy for their disease, even on incomplete evidence, to avoid feeling that they left a potential benefit on the table. Others, particularly those with relatively preserved kidney function and stable disease, may prefer to wait for more mature data or for alternative agents that could emerge. Clinicians will need to explain not only the headline results from DUPLEX but also the nuances of surrogate endpoints, statistical power, and what “no significant difference” in eGFR actually means for an individual’s prognosis.
Health systems and payers, meanwhile, face their own calculus. Orphan-drug exclusivity and the complexity of manufacturing a dual-acting small molecule typically translate into high list prices. Insurers may respond with prior-authorization requirements that hinge on documented proteinuria levels, biopsy-confirmed FSGS, or previous use of standard therapies such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Those access barriers could blunt the real-world impact of the approval unless accompanied by patient-assistance programs and clear clinical guidelines.
Finally, Filspari’s FSGS clearance will likely reverberate beyond nephrology. Other specialties that manage rare, organ-threatening diseases are watching to see how far regulators are willing to lean on surrogate markers when traditional outcome trials are difficult, slow, or ethically complex. If post-approval data ultimately show that robust proteinuria reductions do predict preserved kidney function over time, the case for using similar markers in related conditions will strengthen. If not, FSGS may become a cautionary tale about the limits of surrogates and the importance of waiting for hard endpoints before reshaping standards of care.
For now, Filspari offers something that FSGS patients have not had before: an FDA-recognized, disease-specific option grounded in modern understanding of glomerular injury. Its arrival does not end the search for better therapies or more definitive evidence, but it marks a turning point in how the field thinks about risk, benefit, and proof in the face of a relentless, often silent kidney disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
